Biofrontera Inc.
Ameluz
moderate to severe acne vulgaris (AV)
Resolved
54days ago
Phase 2 readout · May 14, 2026
What's at stake
Phase 2 trial results for Ameluz in moderate to severe acne vulgaris (AV) are due May 14, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“positive results of its Phase 2b clinical trial evaluating Ameluz ® topical gel, 10% used in combination with the RhodoLED ® red-light lamp series for the treatment of moderate to severe acne vulgaris (AV).”